Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib tablet formulation gastrointestinal tolerability study in advanced or metastatic renal cell carcinoma
ACTRN12625001422415Phase 2Not yet recruiting
- Sponsor
- Azurity Pharmaceuticals
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of cabozantinib in renal cell carcinoma (RCC) (2 arms), sponsored by Azurity Pharmaceuticals. Primary endpoints: Incidence of diarrhea of any grade related to study treatment and Dose reduction, interruption, or discontinuation due to adverse events. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ACTRN12625001422415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001422415.